Drug Shortage Report for JAMP RIVASTIGMINE
| Report ID | 251935 |
| Drug Identification Number | 02485362 |
| Brand name | JAMP RIVASTIGMINE |
| Common or Proper name | Rivastigmine Hydrogen Tartrate Capsules |
| Company Name | JAMP PHARMA CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 1.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 56 |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-03-03 |
| Estimated end date | 2025-06-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-03-04 |
| Company comments | Allocation |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-03-04 | French | Compare |
| v1 | 2025-03-04 | English | Compare |
Showing 1 to 2 of 2